Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship
American Society of Clinical Oncology Educational Book · 2025-06 · 45 (3)
DOI: 10.1200/edbk-25-472902 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2025-06. Verfasst von Arielle Elkrief und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Montreal Hospital Research Centre, Cancer Axis, Montreal, Canada. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Antimicrobial Stewardship, Neoplasms, Anti-Bacterial Agents. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 130 Literaturangaben.
Abstract (Originalsprache)
The gut microbiota has emerged as a critical determinant of immune checkpoint inhibitor (ICI) efficacy, resistance, and toxicity. Retrospective and prospective studies profiling the taxonomic composition of intestinal microbes of patients treated with ICI have revealed specific gut microbial signatures associated with response. By contrast, dysbiosis, which can be caused by chronic inflammatory processes (such as cancer) or comedications, is a risk factor of resistance to ICI. Recent large-scale meta-analyses have confirmed that antibiotic (ATB) use before or during ICI therapy alters the microbiota repertoire and significantly shortens overall survival, even after adjusting for prognostic factors. These results underscore the importance of implementing ATB stewardship recommendations in routine oncology practice. Microbiota-centered interventions are now being explored to treat gut dysbiosis and optimize ICI responses. Early-phase clinical trials evaluating fecal microbiota transplantation (FMT) from ICI responders or healthy donors have shown that this approach is safe and provided preliminary data on potential efficacy to overcome both primary and secondary resistance to ICI in melanoma, non–small cell lung cancer, and renal cell carcinoma. More targeted interventions including live bacterial products including Clostridium butyricum and Akkermansia massiliensis represent novel microbiome-based adjunct therapies. Likewise, dietary interventions, such as high-fiber diets, have shown promise in enhancing ICI activity. In this ASCO Educational Book, we summarize the current state-of-the-evidence of the clinical relevance of the intestinal microbiota in cancer immunotherapy and provide a practical guide for ATB stewardship.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Montreal Hospital Research Centre, Cancer Axis, Montreal, Canada.
- University of Montreal Hospital Centre, Department of Hematology-Oncology, Montreal, Canada.
- INSERM U1015, Equipe Labellisée - Ligue Nationale contre le Cancer, Villejuif, France.
- Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
- Gustave Roussy, ClinicObiome, Villejuif, France.
- Université Paris-Saclay, Faculty of Medicine, Kremlin-Bicêtre, France.
Zitieren
APA
Elkrief, A., Routy, B., Derosa, L., Bolte, L., Wargo, J. A., McQuade, J. L., & Zitvogel, L. (2025). Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship. American Society of Clinical Oncology Educational Book, 45(3). https://doi.org/10.1200/edbk-25-472902
Vancouver
Elkrief A, Routy B, Derosa L, Bolte L, Wargo JA, McQuade JL, et al. Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship. American Society of Clinical Oncology Educational Book. 2025;45(3). doi:10.1200/edbk-25-472902
BibTeX
@article{Elkrief2025,
author = {Elkrief, Arielle and Routy, Bertrand and Derosa, Lisa and Bolte, Laura and Wargo, Jennifer A and McQuade, Jennifer L and Zitvogel, Laurence},
title = {Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship},
journal = {American Society of Clinical Oncology Educational Book},
year = {2025},
volume = {45},
number = {3},
doi = {10.1200/edbk-25-472902}
}
EUVIMED